上海医药集团股份有限公司关于召开2025年第二次临时股东大会的通知
Filed with SSE · · 7 pages · Chinese
On 6ix: 6ix.com/news/2025-115
l 股东大会召开日期:2025年12月9日 l 本次股东大会采用的网络投票系统:上海证券交易所股东大会网络投票系统 一、召开会议的基本情况 (一)股东大会类型和届次 (二)股东大会召集人:董事会 (三)投票方式:本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间:2025 年 12 月 9 日 14 点 00 分 召开地点:中国上海市黄浦区太仓路 200 号上海医药大厦二楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统:上海证券交易所股东大会网络投票系统 网络投票起止时间:自2025 年 12 月 9 日 至2025 年 12 月 9 日 采用上海证券交易所网络投票系统,通过交易系统投票平台的投票时间为股东大会召开当日的交易时间段,即 9:15-9:25,9:30-11:30,13:00-15:00;通过互联
Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix
Earlier from Shanghai Pharmaceuticals
- Announcement on Approval of Eslicarbazepine Acetate Tablets by the U.S. FDA
- Announcement on Obtaining Approval for Production of Tofacitinib Citrate Sustained-Release Tablets
- Announcement on Resolutions of the 25th Meeting of the 8th Board of Directors
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on the Subsidiary Becoming the Marketing Authorization Holder of Amisulpride Orally Disintegrating Tablets
Later from Shanghai Pharmaceuticals
- Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on the Termination of the Cooperation Agreement with Guizhou Shenuo Biotechnology Co., Ltd.
- Announcement on Amisulpride Orodispersible Tablets Passing the National Medical Insurance Negotiation and Being Successfully Included in the National Medical Insurance Catalog
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on the Approval of the Marketing Authorization Application for Sitagliptin Fumarate Tablets (SPH3127 Tablets)
Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Pharmaceuticals